Fenofibrate - Vectura

Drug Profile

Fenofibrate - Vectura

Alternative Names: Triglide

Latest Information Update: 14 Jul 2016

Price : $50

At a glance

  • Originator SkyePharma Canada; SkyePharma PLC
  • Developer Vectura
  • Class Antihyperlipidaemics; Benzophenones; Butyric acids; Fibric acid derivatives; Propionates; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia

Most Recent Events

  • 12 Jan 2010 Sciele Pharma is now called Shionogi Pharma
  • 09 Oct 2008 Sciele Pharma has been acquired by Shionogi
  • 16 Jun 2006 First Horizon Pharmaceutical Corporation is now called Sciele Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top